Drug intelligence / Profile preview

ALDP021

Development stage: Preclinical
Lead developer: Alixer Nexgen Therapeutics
Modality: Small Molecules
Administration: Intranasal

Overview

**ALDP021** is an investigational intranasal fixed-dose combination being developed by Alixer Nexgen Therapeutics for moderate-to-severe seasonal and perennial allergic rhinitis. It combines ALDP001, a small-molecule antagonist of histamine H1, H2, and H4 receptors, with an unspecified topical corticosteroid intended to provide local anti-inflammatory activity. The program is described by its sponsor as clinical stage; no exact development phase for ALDP021 itself was specified.

Targets

HRH4 (Histamine H4 receptor)HRH2 (Histamine H2 Receptor)HRH1 (Histamine H1 Receptor)

Beyond the preview

Go deeper on ALDP021.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALDP021.

Explore the full profile